New HIV Entry Inhibitors Using Designed Ankyrin Repeat Proteins
Author Information
Author(s): Schweizer Andreas, Rusert Peter, Berlinger Livia, Ruprecht Claudia R., Mann Axel, Corthésy Stéphanie, Turville Stuart G., Aravantinou Meropi, Fischer Marek, Robbiani Melissa, Amstutz Patrick, Trkola Alexandra
Primary Institution: Division of Infectious Diseases, University Hospital Zurich
Hypothesis
Can designed ankyrin repeat proteins (DARPins) be developed as effective inhibitors of HIV entry?
Conclusion
The study successfully developed CD4-specific DARPins that potently inhibit HIV entry with high specificity and low production costs.
Supporting Evidence
- The DARPins showed high affinity for CD4 with dissociation constants in the low nanomolar range.
- All tested DARPins inhibited HIV entry in both cell line and primary cell-based infection systems.
- The 2nd series DARPins exhibited significantly improved potency compared to the 1st series.
- DARPins did not affect CD4-independent virus entry.
- CD4-specific DARPins did not induce downregulation of CD4 on T cells.
- DARPins showed no cytotoxic effects on primary cells.
Takeaway
Scientists created special proteins that can stop HIV from entering cells, which could help in preventing the virus from spreading.
Methodology
The study used ribosome display to select DARPins that bind specifically to the CD4 receptor and tested their ability to inhibit HIV entry in various assays.
Limitations
The variability in the effectiveness of DARPins against different HIV strains may limit their use in diverse populations.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website